Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James M Backes

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
Hospital Pharmacy|December 6, 2014
Krill oil for cardiovascular risk prevention: is it for real?James M Backes, Patricia A Howard
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|April 9, 2026
Lp(a): A potentially modifiable cardiovascular risk factorDaniel E Hilleman, James M Backes
Future Cardiology|March 1, 2021
New and emerging lipid-lowering therapyJames M Backes, Daniel E Hilleman
The Annals of Pharmacotherapy|January 27, 2005
Effect of lipid-lowering drug therapy on small-dense low-density lipoproteinJames M Backes, Cheryl A Gibson
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|September 19, 2024
A Clinicians Guide to Recommending Common Cholesterol-Lowering Dietary SupplementsJames M Backes, Daniel E Hilleman
The Annals of Pharmacotherapy|January 29, 2003
Association of HMG-CoA reductase inhibitors with neuropathyJames M Backes, Patricia A Howard
Atherosclerosis|February 5, 2003
Re: Gómez-Gerique, et al. Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atherosclerosis 2002;162:245-51Patrick M Moriarty, James M Backes
Future Cardiology|January 16, 2024
Lipid lowering therapy: implications of recent clinical trialsJames M Backes, Daniel E Hilleman
Pharmacotherapy|April 7, 2022
Statin-associated muscle symptoms-A review: Individualizing the approach to optimize careBarbara S Wiggins, James M Backes, Daniel Hilleman
Journal of Clinical Lipidology|October 19, 2019
Pseudohypertriglyceridemia-Raising clinical awarenessJames M Backes, Thomas Dayspring, Patrick M Moriarty
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
Hospital Pharmacy|December 6, 2014
Krill oil for cardiovascular risk prevention: is it for real?James M Backes, Patricia A Howard
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|April 9, 2026
Lp(a): A potentially modifiable cardiovascular risk factorDaniel E Hilleman, James M Backes
Future Cardiology|March 1, 2021
New and emerging lipid-lowering therapyJames M Backes, Daniel E Hilleman
The Annals of Pharmacotherapy|January 27, 2005
Effect of lipid-lowering drug therapy on small-dense low-density lipoproteinJames M Backes, Cheryl A Gibson
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|September 19, 2024
A Clinicians Guide to Recommending Common Cholesterol-Lowering Dietary SupplementsJames M Backes, Daniel E Hilleman
The Annals of Pharmacotherapy|January 29, 2003
Association of HMG-CoA reductase inhibitors with neuropathyJames M Backes, Patricia A Howard
Atherosclerosis|February 5, 2003
Re: Gómez-Gerique, et al. Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atherosclerosis 2002;162:245-51Patrick M Moriarty, James M Backes
Future Cardiology|January 16, 2024
Lipid lowering therapy: implications of recent clinical trialsJames M Backes, Daniel E Hilleman
Pharmacotherapy|April 7, 2022
Statin-associated muscle symptoms-A review: Individualizing the approach to optimize careBarbara S Wiggins, James M Backes, Daniel Hilleman
Journal of Clinical Lipidology|October 19, 2019
Pseudohypertriglyceridemia-Raising clinical awarenessJames M Backes, Thomas Dayspring, Patrick M Moriarty
Pageof 4